VOX Vox Valor Capital Limited

RNS Number:4168J
VASTox plc
26 September 2006

                                   VASTox plc
                          ("VASTox" or "the Company")

                       VASTOX PLC ANNOUNCES BOARD CHANGES


Oxford, UK, 26 September 2006 - VASTox plc (AIM: VOX), a leading UK
biotechnology company, announces today a number of changes to the composition of
its Board of Directors.

Appointment of Barry Price, PhD as Non-executive Chairman

Professor Stephen Davies today steps down as VASTox's Non-executive Chairman and
takes a Non-executive Director position.  He is replaced by Barry Price, PhD,
who also takes the role of Chair of VASTox's Nominations Committee.

Professor Davies has been Chairman since he founded VASTox in January 2003 and
has guided the Company through a successful flotation in October 2004 and a
growth phase that sees it now employing 50 scientists and managers.  Professor
Davies is stepping down as Chairman to focus more time on his new role as
Waynflete Professor and Chairman of Chemistry at the University of Oxford, one
of the most prestigious academic posts in UK science.

Barry Price, PhD (aged 63) has a wealth of industry and Board-level expertise
and brings to VASTox 39 years' of experience in the pharmaceutical and life
sciences industries.  He is currently Chairman of Antisoma plc (LSE: ASM) and
Biowisdom Limited, and Non-Executive Director of Shire plc (LSE: SHP, NASDAQ:
SHPGY, TSX: SHQ). Dr Price has been a Director of Shire for ten years during
which time he has seen it grow to become one of the UK's largest life sciences
companies.

Professor Stephen Davies said: "I have been Chairman of VASTox for over three
years and have taken a hands-on role in the early years of the Company's
operations.  VASTox is now a strong business with a very capable management team
and so the time is right for the Company to appoint a new Chairman who can guide
it through the next stage of growth.  In Barry Price we have attracted a
Chairman with proven experience in growing life science companies as well as
significant pharmaceutical industry knowledge.  I warmly welcome Barry to the
Board and look forward to working with him."

Barry Price, PhD, commented: "I am delighted to be offered the role of Chairman
of VASTox plc.  I have been impressed with the Company's evolution, the calibre
of its managers, and as a chemist, I can clearly see the potential of VASTox's
approach and value to the pharmaceutical industry.  The Company has an exciting
future and I intend to work closely with the Board and Executive team to ensure
the business maximises both its opportunities for growth and the creation of
value for shareholders."

Appointment of Colin Wall, PhD as Non-executive Director

Also today, VASTox announces the appointment of Colin Wall, PhD (aged 57) as
Non-executive Director. He replaces John Montgomery, who today resigns from his
role as Non-executive Director.

John Montgomery co-founded VASTox with Professor Davies in January 2003 and was
the Company's Financial Director during its early growth stage.  He will step
down to focus more on his role as Bursar of St John's College at the University
of Oxford.

As part of his role, Dr Wall has been appointed Chair of the Remuneration
Committee. He will also be designated Senior Independent Non-executive Director
and will act as an independent conduit for shareholders, in line with the
recommendations of the Combined Code of Corporate Governance.  Colin has over 40
years' of commercial experience including significant board-level experience at
a number of public and private companies.  He is currently Chairman of Copley
Wall & Associates Ltd and Elvstrom Sobstad (UK) Ltd.  He is also a Non-executive
Director of Elvstrom Sails A/S.

Steven Lee, PhD, Chief Executive Officer added: "I am very pleased to welcome
Barry Price and Colin Wall to the Board of VASTox.  Barry has an impeccable
reputation within the life sciences industry and brings to VASTox a wealth of
experience as we pursue our growth ambitions.  Colin is another high calibre
appointment to VASTox who will complement the balance of commercial, scientific
and industry skills on the Board.
      
"On behalf of the Board, I would like to thank Professor Stephen Davies for his
contributions as founder and Chairman of VASTox to date.  The Company has made
great strides under his guidance and I have no doubt that Steve will continue to
make a valuable input as a Non-executive Director.  I would finally like to
thank John Montgomery on behalf of the whole Board for his contributions since
the inception of VASTox."

AIM Rules Disclosure

Barry Price, PhD is currently a director of Biowisdom Limited, Antisoma plc and
Shire plc.  In the previous five years, he has held directorships at Chemunex SA
and Pharmagene plc.

Colin Wall, PhD, is currently a director of Copley Wall & Associates Limited,
Elvstrom Sobstad (UK) Limited and Elvstrom Sails A/S.  In the previous five
years, he has held directorships at The Pygmalion Group, Torex plc and Isoft
plc.

VASTox confirms that, save for the above, there are no other matters under
paragraph (g) of Schedule 2 of the AIM rules to be announced.


                                    - ends -


For more information please contact:

VASTox
Steven Lee, PhD, Chief Executive Officer                 Tel: +44 (0)1235 443910
Darren Millington, ACMA, Chief Financial Officer

Citigate Dewe Rogerson                                   Tel: +44 (0)207 6389571
David Dible / Mark Swallow / Valerie Auffray


About VASTox plc

VASTox is a chemical genomics technology company that discovers and develops
proprietary novel drugs and provides services to the pharmaceutical industry.
The company's most advanced drug development programme is focused on developing
a new treatment for Duchenne muscular dystrophy based on the up-regulation of
utrophin. A second drug development programme for spinal muscular atrophy is
also progressing rapidly. VASTox has four additional programmes focused on
osteoarthritis, cancer, tuberculosis and stem cell therapies, which are expected
to be out-licensed prior to entering the clinic.

The company's technology platform, which uses zebrafish and fruitflies, has the
potential to dramatically decrease the time and cost of drug discovery and
development. This is because using whole organisms allows it to carry out high
volume, high content screening, which delivers data that are highly predictive
of the efficacy and toxicity of potential drug compounds in humans. VASTox is
growing revenues based on marketing its unique technology platform and its
chemistry expertise.  The company listed on the AIM market of the London Stock
Exchange in October 2004.

Further information about the company is available at www.vastox.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

BOAPUUPWBUPQGPA

Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Jul 2023 to Jul 2024